What they were paid
ENANTA PHARMACEUTICALS Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $65,000 | $0 | $61,332 | $0 | $126,332 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ENANTA PHARMACEUTICALS INC DEF 14A filed January 26, 2026, accession 0001193125-26-022558, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025ENANTA PHARMACEUTICALS pays directors a $50,000 cash retainer and $61,332 in Stock Options.
Committees
FY2025 · as the proxy prints themAudit · Nominating/Governance
The rest of the ENANTA PHARMACEUTICALS board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Bruce L.A. Carter, Ph.D | Chair of the Board | $158,832 |
| Jay R. Luly, Ph.D | Director | $0 |
| Kristine Peterson | Independent Director | $131,332 |
| Mark G. Foletta | Independent Director | $136,332 |
| Terry C. Vance | Independent Director | $138,832 |
| Yujiro Hata | Independent Director | $123,832 |
The full ENANTA PHARMACEUTICALS compensation record
free company briefThis page is one director within ENANTA PHARMACEUTICALS's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat